
Study Highlights Disparities in Access to JAK Inhibitors for Alopecia Areata
Despite Janus-Kinase (JAK) inhibitors’ widely known efficacy for alopecia areata, new research highlights that disparities in access remain due to such barriers as coverage denials for patients on public insurance versus private insurance.1 These data were …